Goran Dubravcic
”We show increasing sales but there is still a lot of untapped potential”, says new CEO of PHI
PHI specializes in non-invasive cell analysis, enabling researchers to study cells without disrupting their natural state. The company’s products...
PHI’s CEO comments on the approved US listing
Phase Holographic Imaging has been approved for a...
Shift to regenerative medicine increases growth prospects for PHI
With a sharp focus on expanding its market...
Altium fuels PHI’s forward drive
PHI’s largest investor, Altium S.A., has intensified its...
PHI´s CEO comments on latest advancements
In 2022, medtech company Phase Holographic Imaging conducted...
PHI catches eye of major investor
The private Swiss Distributor and Investment Company Altium...
Notiser
Ultomiris visar stark överlevnad i HSCT-TMA-studie
Circio presenterar lovande TG01-data
Cinclus Pharma slipper barnstudier för linaprazan glurate
Thor Medical tecknar avtal värt 200 MNOK
Genmabs Epcoritamab visar höga responsnivåer i DLBCL-studie
NYHETSBREV
NYHETER
Lovande 4-månadersdata från Cerenos Expanded Access Program
AcuCort stärker lansering med TO2-injektion
AstraZeneca i miljardavtal inom AI
Kommande event!
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region’s leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Du är värd det bästa!
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto
Krönikor
Bispecifikt och kinesiskt det nya svarta inom cancer
Riskkapitalcykeln fullständig – vi är tillbaka där vi började
